Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients

The US Food and Drug Administration has registered 13 multiple sclerosis (MS) disease-modifying therapies (DMTs). The medications are not interchangeable as they vary in route of administration, efficacy, and safety profile. Selecting the appropriate MS DMT for individual patients requires shared de...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourdette, Dennis N., Hartung, Daniel M., Whitham, Ruth H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828681/
https://www.ncbi.nlm.nih.gov/pubmed/27104069
http://dx.doi.org/10.1212/CPJ.0000000000000208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828681/
https://www.ncbi.nlm.nih.gov/pubmed/27104069
http://dx.doi.org/10.1212/CPJ.0000000000000208

Ejemplares similares